Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.

Authors: Umang Swami, Yeonjung Jo, Chadi Hage Chehade, Zeynep Irem Ozay, Nicolas Sayegh, Georges Gebrael, Micah Ostrowski, Patrick Campbell, Siqi HU, Gliceida M Galarza Fortuna, Vinay Mathew Thomas, Haoran Li, Ryon P Graf, Soumyajit Roy, Benjamin L. Maughan, Avirup Guha, Irbaz Bin Riaz, Emmanuel S. Antonarakis, Rana R. McKay, Neeraj Agarwal

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.95

Source: Full article

Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.

Abstract